Grace Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Grace Therapeutics, Inc. (GRCE) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 198.13 thousand shares for the 3-month period ending 2024-06-30, per its 10-Q filed 2024-08-09.
Discontinued › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2024-08-09
- Grace Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2024-06-30 was 198.13K shares.
- Grace Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2022-12-31 was 0.00 shares.
- Grace Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 607.67K shares, a 59.01% decline from fiscal 2023.
- Grace Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 1.48M shares, a 29.92% decline from fiscal 2022.
- Grace Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 2.12M shares.
- Grace Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2020 was 6.14M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|
| 2024-06-30 | 198.13K shares 10-Q · filed 2024-08-09 | ||
| 2024-03-31 | 607.67K shares 10-K · filed 2024-06-21 | ||
| 2023-12-19 | 161.17K shares 10-K · filed 2024-06-21 | ||
| 2023-07-14 | 446.50K shares 10-K · filed 2024-06-21 | ||
| 2023-03-31 | 1.48M shares 10-K · filed 2023-06-23 | ||
| 2022-12-31 | 0.00 shares 10-Q · filed 2023-02-14 | ||
| 2022-03-31 | 2.12M shares 10-K · filed 2022-06-21 | ||
| 2020-03-31 | 6.14M shares 10-K · filed 2020-06-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |